AKT1 and non-small cell lung carcinoma: Furthermore, icotinib was also found capable of suppressing the Akt signaling pathway activation in human NSCLC cells (24), which was associated with miR-22 (25), hypothesizing that miR-22 may affect the icotinib efficacy in NSCLC.